OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

October 6th 2020

Patricia Pautier, MD, discusses limitations in leiomyosarcoma.

Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic Malignancies

October 6th 2020

Ajeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Gainor on the Evolving Lung Cancer Armamentarium

October 5th 2020

Justin F. Gainor, MD, discusses the evolving lung cancer armamentarium.

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

October 5th 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Dr. Azad on the Benefit of Adding Enzalutamide to ADT in mHSPC

October 5th 2020

Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma

October 5th 2020

William W. Tseng, MD, discusses the rationale for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

October 5th 2020

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

Dr. Vesole on the Advantages of CAR T-Cell Therapy in Multiple Myeloma

October 5th 2020

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

October 3rd 2020

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Dr. Strosberg on Retreatment With Lutathera in Advanced NETs

October 3rd 2020

Jonathan Strosberg, MD, discusses retreatment with Lutathera in advanced neuroendocrine tumors.

Dr. Chauhan on the Role of Lutathera in NETs

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of Lutathera in neuroendocrine tumors.

Dr. Bhat on the Role of Targeted Therapies in CLL

October 2nd 2020

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

Dr. Duval on the Use of MSI-H as a Biomarker of Response in Patients With Cancer

October 2nd 2020

Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.

Dr. Gerber on the Rationale to Combine Immunotherapy With Radiation in Lung Cancer

October 2nd 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

Dr. Silberman on Treatment Options in Early-Relapse Multiple Myeloma

October 2nd 2020

Rebecca Silbermann, MD, MMS, discusses current treatment options for fit patients with multiple myeloma who experience early relapse.

Dr. Abraham on the Surgical Management of TGCT

October 2nd 2020

John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.

Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE Trial

October 2nd 2020

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Dr. Wolin on the Safety of Lutathera in Advanced NETs

October 2nd 2020

Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.